Efficacy

Trelegy Ellipta: Efficacy in Asthma Management

Trelegy Ellipta, a combination of fluticasone furoate, umeclidinium, and vilanterol, is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and is also approved for asthma in certain patients. The efficacy of Trelegy Ellipta for asthma was evaluated in clinical trials involving patients with a history of exacerbations. In these studies, Trelegy Ellipta demonstrated a significant reduction in the rate of moderate/severe exacerbations compared to dual therapy (fluticasone furoate/vilanterol or umeclidinium/vilanterol) and improved lung function as measured by FEV1 (forced expiratory volume in one second). The triple therapy has been shown to improve asthma control and quality of life in patients with uncontrolled asthma despite standard treatment.

It is important to note that Trelegy Ellipta is not indicated for the relief of acute bronchospasm. The medication is designed for once-daily use via inhalation, and its efficacy in asthma is particularly notable in patients who have a history of exacerbations despite receiving inhaled corticosteroids/long-acting beta2-adrenergic agonists (ICS/LABA). The addition of the long-acting muscarinic antagonist (LAMA) component, umeclidinium, provides an additional mechanism of action to improve asthma control.

Tezspire: A Novel Approach to Severe Asthma

Tezspire (tezepelumab-ekko) represents a novel approach to the treatment of severe asthma. It is a human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in the initiation and persistence of airway inflammation. Tezspire has been studied in a range of patients with severe, uncontrolled asthma, including those with varying levels of eosinophils, a type of white blood cell associated with inflammation in asthma.

The efficacy of Tezspire in severe asthma was demonstrated in the PATHFINDER clinical program, which included the pivotal NAVIGATOR Phase 3 trial. In this trial, Tezspire significantly reduced the annualized rate of asthma exacerbations compared to placebo, showing benefit across a broad population of severe asthma patients regardless of eosinophil counts at baseline. Additionally, improvements were observed in lung function, asthma control, and health-related quality of life. Tezspire is the first biologic to show efficacy in a broad population of severe asthma patients, including those with low eosinophil levels, suggesting its potential as a valuable treatment option for a wider range of patients.